Skip to main content
    S

    Strata Critical Medical, Inc. (SRTA)

    Official site

    HEALTHCARE • MEDICAL CARE FACILITIES • NASDAQ

    $5.42
    -0.09 (-1.63%)

    Market Cap: $492.15M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Strata Critical Medical, Inc. (SRTA) Earnings: Report Dates and Results

    Updated Nov 3, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Strata Critical Medical (SRTA) is expected to report earnings on Mar 1, 2027. In the quarter ended Sep 30, 2026, Strata Critical Medical reported EPS of -$0.05, below the $0.01 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    57%(12/21)
    Avg Surprise
    -44.06%

    Upcoming Estimates

    Reports Mar 1, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.02
    Range$0.01 - $0.03
    6 analysts
    Revenue Consensus
    $77.48M
    Range$73.89M - $80.53M
    6 analysts
    Reports May 4, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.01
    Range-$0.01 - $0.02
    4 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.02-50.0%
    60d ago$0.02-50.0%
    30d ago$0.02-50.0%
    7d ago$0.02-50.0%
    Current$0.01
    Revenue Consensus
    $79.27M
    Range$76.90M - $82.10M
    3 analysts

    Next Report

    SRTA has an expected report date of Mar 1, 2027.

    SRTA Earnings Call

    The latest SRTA earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 21 quarters below that had an estimate, SRTA beat 12, missed 6 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $74.08M, up 50.3% from $49.30M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.05$0.01-$0.05 - $0.01-600.00%MissN/A41 up, 0 downNov 3, 2026$74.08M
    Jun 30, 2026-$0.01-$0.01-$0.03 - -$0.010.00%In lineN/A41 up, 0 downAug 4, 2026$72.51M
    Mar 31, 2026$0.04-$0.04-$0.04 - -$0.04+200.00%BeatN/A10 up, 0 downMay 6, 2026$67.38M
    Dec 31, 2025-$0.12$0.06N/A-300.00%MissN/A10 up, 0 downMar 3, 2026$66.79M
    Sep 30, 2025-$0.12-$0.02N/A-500.00%MissN/AN/AN/ANov 10, 2025$49.30M
    Jun 30, 2025-$0.04-$0.05N/A+20.00%BeatN/AN/AN/AAug 5, 2025$70.80M
    Mar 31, 2025-$0.07-$0.10N/A+30.00%BeatN/AN/AN/AMay 12, 2025$54.31M
    Dec 31, 2024-$0.13-$0.12N/A-10.60%MissN/AN/AN/AMar 13, 2025$54.36M
    Sep 30, 2024-$0.01-$0.02N/A+50.00%BeatN/AN/AN/ANov 12, 2024$74.88M
    Jun 30, 2024-$0.06-$0.06N/A0.00%In lineN/AN/AN/AAug 7, 2024$67.94M
    Mar 31, 2024-$0.10-$0.11N/A+9.09%BeatN/AN/AN/AMay 7, 2024$51.51M
    Dec 31, 2023-$0.13-$0.12N/A-7.92%MissN/AN/AN/AMar 12, 2024$47.48M
    Sep 30, 2023-$0.02-$0.06N/A+66.67%BeatN/AN/AN/ANov 8, 2023$71.44M
    Jun 30, 2023-$0.09-$0.10N/A+10.00%BeatN/AN/AN/AAug 9, 2023$60.99M
    Mar 31, 2023-$0.14-$0.16N/A+12.50%BeatN/AN/AN/AMay 11, 2023$45.27M
    Dec 31, 2022-$0.22-$0.20N/A-10.00%MissN/AN/AN/AMar 15, 2023$38.13M
    Sep 30, 2022-$0.09-$0.13N/A+30.77%BeatN/AN/AN/ANov 10, 2022$45.72M
    Jun 30, 2022-$0.11-$0.19N/A+42.11%BeatN/AN/AN/AAug 9, 2022$35.63M
    Mar 31, 2022-$0.15-$0.20N/A+25.00%BeatN/AN/AN/AMay 10, 2022$26.63M
    Sep 30, 2021-$0.13-$0.14N/A+7.14%BeatN/AN/AN/ADec 20, 2021$24.62M
    Jun 30, 2021-$0.47-$0.47N/A0.00%In lineN/AN/AN/AAug 16, 2021$12.95M
    Mar 31, 2021-$0.33-$0.03N/AN/AN/A-573.0%N/AN/AMay 17, 2021$9.27M
    Dec 31, 2020-$0.16N/AN/AN/AN/A-328.6%N/AN/AMar 10, 2021$7.99M
    Sep 30, 2020-$0.01N/AN/AN/AN/A-150.0%N/AN/ANov 10, 2020$8.32M
    Jun 30, 2020$0.00N/AN/AN/AN/AN/AN/AN/AAug 13, 2020$3.44M
    Mar 31, 2020$0.07N/AN/AN/AN/AN/AN/AN/AMay 13, 2020$6.45M
    Dec 31, 2019$0.07N/AN/AN/AN/AN/AN/AN/AMar 20, 2020$5.22M
    Sep 30, 2019$0.02N/AN/AN/AN/AN/AN/AN/ANov 13, 2019N/A
    Last 28 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.35, after -$0.30 the year before. It was $0.09 for the year ended Dec 31, 2019, the oldest of the 6 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.35N/A
    Dec 31, 2024-$0.30N/A
    Dec 31, 2023-$0.38N/A
    Dec 31, 2022-$1.50N/A
    Dec 31, 2020-$0.10-211.3%
    Dec 31, 2019$0.09N/A

    Earnings Calls

    The 7 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,100 words across 8 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,1268
    2026Q2Jun 30, 20264,3016
    2026Q1Mar 31, 20265,4008
    2025Q4Dec 31, 20256,0537
    2025Q3Sep 30, 20253,6746
    2025Q2Jun 30, 20254,5858
    2025Q1Mar 31, 20255,5439

    2026Q3 Earnings Call

    Opening remarks

    Mathew Schneider CFO of Clinical Services and Vice President of Finance and Investor Relations Thank you for standing by, and welcome to Strata's conference call and webcast for the quarter ended September 30, 2026. We appreciate everyone joining us today. Before we get started, I would like to remind you of the company's forward-looking statement and safe harbor language. Statements made in this conference call that are not historical facts, including statements about future time periods, may be deemed to constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties, and actual future results may differ materially from those expressed or implied by the forward-looking statements. We refer you to our SEC filings, including our annual report on Form 10-K and our quarterly report on Form 10-Q, each as filed with the SEC, for a more detailed discussion of the risk factors that could cause these differences. Any forward-looking statements provided during this conference call are made only as of the date of this call. As stated in our SEC filings, Strata disclaims any intent or obligation to update or revise these forward-looking statements, except as required by law. During today's call, we will also discuss certain non-GAAP financial measures, which we believe may be useful in evaluating our financial performance. A reconciliation of the most directly comparable historical consolidated GAAP financial measures to those historical non-GAAP financial measures is provided in our earnings press release and investor presentation. Our press release, investor presentation, and our Form 10-Q and 10-K filings are available on the Investor Relations section of our website at ir.stratacritical.com. These non-GAAP measures should not be considered in isolation or as a substitute for financial results prepared in accordance with GAAP. Hosting today's call are our co-CEOs, Will Heyburn and Melissa Tomkiel. I'll now turn the call over to Will.

    William Heyburn Co-CEO Thank you, Matt, and good morning, everyone. Our strong third quarter results speak for themselves. Q3 was not only ahead of our guidance, but also showed Strata's capability to generate significant cash flow with much higher conversion. As more customers turn to our integrated transplant offering for more of their cases, we are demonstrating continued market share gains in clinical services. This helped drive clinical segment revenue growth of more than 20% sequentially versus Q2 2026. As Melissa will discuss in more detail, our go-to-market is all about creating alignment with our customers' objectives and becoming that trusted long-term partner in a space that's becoming far too complex to go it alone. We saw yet another quarter of sequential margin improvement, driven in large part by achieving our 2027 logistics gross margin target well ahead of plan.

    Frequently Asked Questions About SRTA

    When is Strata Critical Medical's next earnings date?

    Strata Critical Medical's next earnings report is expected for Mar 1, 2027.

    Did SRTA beat earnings estimates last quarter?

    No. Strata Critical Medical reported EPS of -$0.05 for the quarter ended Sep 30, 2026, below the $0.01 estimate by 600.00%.

    What EPS do analysts expect from SRTA next quarter?

    The consensus EPS estimate for Strata Critical Medical for the quarter ending Dec 31, 2026 is $0.02 from 6 analysts, with estimates from $0.01 to $0.03.

    How often does SRTA beat earnings estimates?

    Strata Critical Medical beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -145.07%.